MedTech Marketing Intelligence

We monitor and analyze.
You get expert advice to act on.

Competitor monitoring and analysis, translated into product marketing decisions.

  • Company websites
  • Clinical trial registries
  • Press releases
  • Clinical publications
  • Regulatory databases
  • Medical congresses
  • Financial results & earnings calls
  • Social media
  • Other public sources

What we track includes:

  • Product launches
  • Messaging
  • Clinical evidence
  • Partnerships
  • Regulatory developments
  • Market expansion

See what a brief looks like.

Weekly brief · Website messaging

Real-world example*

RivalKite · Intelligence team

to Your team

9 Nov 2026
Clearest benefit
Abbott Volt
Most visible evidence
Boston Scientific
Your opening
Benefit + proof
Website messagingCaptured 9 Nov 2026

Abbott Volt vs Boston Scientific FARAPULSE

How each opens its US page for healthcare professionals.

  • Screenshot of Abbott's Volt PFA System page: Revolt Against the Ordinary. Reengineering PFA with fewer applications and total control.

    Abbott · cardiovascular.abbott · Volt PFA System

    Leads with the benefit

    “Fewer applications and total control.” The evidence sits in the side navigation.

  • Screenshot of Boston Scientific's FARAPULSE PFA Platform page: a Clinical data button in the hero, the FARADIGM trial announcement, and Transformation for every pulse.

    Boston Scientific · bostonscientific.com · FARAPULSE PFA Platform

    Leads with the evidence

    A “Clinical data” button in the hero. A trial announcement competes with the core message.

Our take: Abbott says more clearly why to consider Volt; Boston Scientific makes the evidence easier to find. Neither opening pairs a specific benefit with its proof.

Your next moves

  • 1Lead with one specific procedural benefit and name the step it improves.
  • 2Put the supporting evidence right next to that claim.
  • 3Follow with clear routes to platform details, training and sales contact.

Priority alert · Earnings call

Real-world example*

RivalKite · Intelligence team

to Your team

28 Oct 2026
Priority alertEarnings call

Boston Scientific expects to keep losing PFA share until early 2028.

On the Q3 call, management said EP sales fell 5%: down 8% in the US, up 2% internationally. It expects continued erosion of its PFA share until FARAWAVE Ultra launches, now expected in early 2028.

Why it matters: Abbott's acceleration is clear. How much comes from Boston Scientific, and what it means for your accounts, is not yet known.

Q3 2026 earnings call transcript · 28 Oct 2026Outcome: Investigate

Earlier alerts

  • Boston ScientificEarnings call28 Oct 2026

    A cyberattack cost about $150 million of revenue.

    The outage cost is company-wide, not specific to electrophysiology, so it blurs how much of the 5% EP decline comes from competition.

    MedTech Dive report on the call

  • AbbottResults filing21 Oct 2026

    Electrophysiology sales up 15.5% on a comparable basis.

    Q3 EP sales of $873 million, up 15.0% as reported. The CEO credited the new Volt PFA catheter.

    Abbott results filingAbbott CEO commentary

Monthly review · October 2026

Real-world example*

RivalKite · Intelligence team

to Your team

9 Nov 2026

October 2026: PFA messaging and competition

What changed in October, and where to act, investigate or stay the course.

  • Your EP page opening: a specific benefit with its proofAct now
  • Talk track for EP labs using Boston Scientific until 2028Act now
  • PFA adoption in your EP-lab accountsInvestigate
  • Abbott's efficiency message: fewer applications, light sedationInvestigate
  • FARADIGM trial: FARAFLEX catheter, investigational, not for saleStay the course

Sources

  • Abbott results filingsec.gov · Form 8-K, Exhibit 99.1 · 21 Oct 2026
  • Abbott CEO commentaryabbott.com · 21 Oct 2026
  • Boston Scientific results filingsec.gov · Form 8-K · 28 Oct 2026
  • MedTech Dive report on the callmedtechdive.com · 28 Oct 2026
  • Abbott product page (screenshot)cardiovascular.abbott · Volt PFA System · 9 Nov 2026
  • Boston Scientific product page (screenshot)bostonscientific.com · FARAPULSE PFA Platform · 9 Nov 2026
  • Q3 2026 earnings call transcriptfool.com · 28 Oct 2026

How it works.

  1. 01

    Competitor monitoring.

    We track your competitors' launches, claims, clinical evidence and messaging, and filter out the noise.

  2. 02

    Strategic analysis.

    We connect developments over time and assess what they mean for your competitive position.

  3. 03

    Your next move.

    Prioritized next moves: where to act, what to investigate, and when to stay the course.

We save your team the time competitor intelligence takes.

  • In-house research

    Your expertise. Your limited time.

    Your team knows your products and customers. But competitor research competes with launches, campaigns, and sales requests.

  • Competitive intelligence software

    Powerful tools. More work to put insights into context.

    Platforms collect large amounts of information. Your team still has to work out what it means for your products and customers.

  • RivalKite

    Continuous intelligence, with a product marketing perspective.

    We monitor and analyze your competitors. Senior product marketers tell you what to do about it, from messaging to sales enablement.

Simple pricing.
Start with a 30-day pilot.

See the value of ongoing competitive intelligence before committing to a monthly subscription.

  • Start here

    Pilot

    See what RivalKite can uncover about your competitive landscape.

    €390/ 30 days

    Start a 30-day pilot
    What's included
    • Monitoring of up to 2 competitors
    • 2 intelligence briefs with strategic analysis and next moves
    • End-of-pilot review with prioritized next steps
    • Senior product marketing perspective
    • No long-term commitment

    After 30 days, decide whether to continue with ongoing intelligence. No automatic subscription.

  • Core

    For product marketing teams that need ongoing competitive intelligence.

    €995/ month

    Get started
    What's included
    • Monitoring of up to 3 competitors
    • Ongoing tracking across agreed competitive priorities
    • Weekly intelligence briefs with analysis, implications, and next moves
    • Monthly strategic review
    • Next moves covering positioning, differentiation, messaging, campaigns, sales enablement, and go-to-market decisions
    • Priority alerts for significant competitive developments
  • Extended

    For companies managing a broader or more complex competitive landscape.

    €1,495/ month

    Get started
    What's included

    Everything in Core, plus:

    • Monitoring of up to 5 competitors
    • Monthly comparative deep dive into competitive positioning, messaging, claims, and supporting evidence
    • Identification of differentiation opportunities and competitive vulnerabilities
    • Prioritized next moves based on the comparative analysis
  • Monthly plans: Cancel anytime. Cancellation takes effect at the end of the paid billing period.

Prices exclude VAT, where applicable. Need to monitor more competitors? Contact us for a tailored scope.

Put us to the test.
Your first brief is free.

Tell us who you're competing with, which markets matter, and what you're trying to understand.

No commitment. No sales call required.